TH07 topical treatment for male pattern hair loss

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3, randomized trial will enroll up to 420 men with androgenic alopecia (Hamilton-Norwood III vertex to V) across clinical sites, with participants assigned to one of four arms: TH07 once daily, TH07 twice daily, standard 5% minoxidil, or placebo. TH07 is a combined topical spray containing minoxidil 5%, finasteride 0.1%, and latanoprost 0.03%. Participants will apply the assigned product for 24 weeks while being monitored for hair count changes and safety outcomes. The primary comparison is change in hair count between groups at the end of treatment, with regular clinic visits to document efficacy and adverse events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Males, 18 to 49 years of age on the date of enrollment.
* Presenting with androgenic alopecia measured as III vertex to V on Hamilton Norwood Scale.
* Body Mass Index (BMI) in the range of 19 to 35 kg/m2.
* Not administered any systemic or topical treatment for AGA during the last 90 days.
* Willing to comply with the following restrictions for the duration of trial participation:

  1. Any systemic or topical treatment of any system of medicine (other than trial treatment) for AGA.
  2. Hair dyes, hair texturizers, relaxers etc.
  3. Any new vitamins or nutritional supplements that are currently not being administered.
  4. Tattooing in the trial target area.
  5. Blood donations.
  6. OTC hair restorers.
  7. Do not expose your pregnant partner to your hands/skin where the drug might be present.
  8. Participation in any other drug or device trials during the course of this trial.

     Note: However, the following shall be permissible:
  9. Non-medicated \& anti-dandruff shampoos, scalp/hair applications including styling gels, sprays, mousse (styling gels, sprays, mousse etc. not to be used on the days of trial visits to the clinic.
  10. Current regimen (if any) of vitamins and nutritional supplements.
* Willing and able to provide written informed consent for participation in the trial and to comply with all trial requirements.
* Availability of and usage familiarity with a personal mobile phone (Android or iOS) with internet connectivity and a personal email address.

Exclusion Criteria:

* History of scalp treatment including though not limited to any of the following:

  1. Hair transplant or extension surgery.
  2. Hair weaving.
  3. Laser or light therapy on the scalp in the last 6 months.
  4. Micro-needling or intradermal therapy (mesotherapy) on the scalp including PRP in the last 6 months.

  5-Any other surgical treatment for hair loss
* Any of the following hair styles:

  1.Shaved scalp. 2-Use of occlusive wig, hair extensions, non- breathable wigs.
* Known or presumed hypersensitivity to any trial treatment medication; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of investigator may affect the outcome of trial.
* Any other significant abnormalities indicating of severe, acute or chronic medical condition(s) that may lead to hair loss or otherwise interfere with the interpretation of trial results.
* History or likelihood of use of any of the specified medicines.
* History or clinical diagnosis of any of the specified medical conditions.
* Participation in any investigational or marketed drug or device trial in the last 90 days prior to screening for this trial.
* Any other condition that in the opinion of the investigator makes the patient unsuitable for inclusion in the trial.

Where it's running

• YVR Aesthetic Training and Study Centre.
  Vancouver, British Columbia, Canada Recruiting

Study contacts

• Study coordinator: Edouard AL-Chami
• Email: ealchami@triplehair.ca
• Phone: 647-453-3253

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dual treatment with KeraFactor and Revian LED for female pattern hair loss

  This study tests whether using a scalp-stimulating serum together with a Revian LED cap helps women with androgenic alopecia grow more hair than each treatment alone or placebo.

  Recruiting K. Kay Durairaj, MD, FACS, A Medical Corporation · Pasadena, California · NCT07810504

• Two hair supplements for men with androgenic alopecia

  This study tests two daily hair supplement formulations against placebo to see if they improve hair growth and perceived hair quality in men with mild to moderate androgenetic alopecia over 84 days.

  Recruiting at 6 sites Activ'inside · Rende, Cosenza and 5 other locations · NCT07806474

• JAK2 levels in balding and non-balding scalp before and after topical minoxidil

  This will test whether three months of topical minoxidil changes JAK2 protein levels in the scalps of adults (18–50) with mild to moderate androgenetic alopecia.

  Recruiting Kasr El Aini Hospital · Cairo, Cairo Governorate · NCT07563036

• 2-Deoxy-D-ribose hydrogel versus 5% minoxidil for androgenetic alopecia

  This trial will test whether a once-daily topical 2‑Deoxy‑D‑ribose hydrogel is as effective and safe as 5% minoxidil for adults aged 18 to 50 with mild to moderate androgenetic alopecia.

  Recruiting Kasr El Aini Hospital · Cairo, Cairo Governorate · NCT07502976

• Umbilical cord mesenchymal stem cell exosome treatment for male pattern hair loss in young men

  This trial will test whether injections of umbilical cord mesenchymal stem cell exosomes can regrow hair or slow hair loss in men aged 18–35 with androgenic alopecia compared with topical 5% minoxidil.

  Recruiting Phase 1/2 Shenzhen People's Hospital · Shenzhen, Guangdong · NCT07203599

• Autologous hair follicle secretome treatment for androgenic alopecia

  This will test whether injecting a person's own hair-follicle secretome into the scalp can help adults with androgenic alopecia grow thicker, denser hair.

  Recruiting Acorn Biolabs Inc. · West Hollywood, California · NCT07107841

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.